15 June 2026
15 June 2026
The study included 639 patients, 79.8% of whom had previously received covalent BTK inhibitors.
The approvals are based on data from the pivotal Phase III LITESPARK-022 trial, which enrolled 1,841 patients.
TRACE-CPE will investigate whether rapid molecular screening for CPE can enhance infection prevention, optimise NHS resources, and contribute to future policy.
The study is enrolling up to 300 US patients with CRS to evaluate the ESSpand DCB with endoscopic sinus surgery.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
